We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Silenced Gene May Treat Cancer

By Biotechdaily staff writers
Posted on 25 Oct 2005
Restoring a gene often silenced in lung cancer causes the cells to self-destruct, suggesting a new strategy for treating the disease. More...


Researchers focused on a gene known as WWOX, which is silenced in a large majority of lung cancers as well as in cancers of the breast, ovary, prostate, bladder, esophagus, and pancreas. In both laboratory and animal experiments, restoring the silenced WWOX gene slowed or stopped the cells' growth. These findings were published in the October 13, 2005, online edition of the Proceedings of the [U.S.] National Academy of Sciences.

WWOX is a tumor-suppressor gene. The WWOX protein is missing in cells making up many lung tumors, and in 62% of cases, the gene is turned off by a chemical process known as methylation. In the current study, researchers used three different lines of laboratory-grown lung-cancer cells that were missing WWOX protein. They engineered a virus to carry working copies of the WWOX gene into the three cell lines. After five days, cells having an active WWOX gene died, self-destructed by apoptosis. In contrast, the lung cancer cells that lacked the WWOX gene continued growing and increased in number nearly five-fold or six-fold.

The researchers also took some lung-cancer cells to which they had added working copies of the WWOX gene and transplanted the cells into mice. A group of control mice received lung-cancer cells without the WWOX gene. After 28 days, the mice that received tumor cells with no WWOX gene had developed tumors. Of the mice that received tumor cells with the gene, 60% in one group and 80% in another group showed no tumors.

"Our study is a proof of principle,” said co-author Kay Huebner, professor of molecular biology, immunology, and medical genetics at the Comprehensive Cancer Center at Ohio State University (OSU, Columbus, USA).

"We don't believe that using WWOX as a therapy will necessarily eradicate tumors,” added first author Muller Fabbri, a postdoctoral fellow at OSU, "but we do believe that this kind of gene therapy might be useful when used in combination with chemotherapy and other therapies.”



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.